Table 1.
Baseline patients’ characteristics
| Characteristic | CYP3A4*1G | ||
|---|---|---|---|
| Total number of patients (n = 82) | wt/wt (n = 69) | wt/*1G (n = 13) | |
| Age (years) | 62 ± 9.5 | 63.5 ± 9.3 | 68.4 ± 9.7 |
| BMI (kg/m2) | 28.69 ± 4.83 | 29.0 ± 4.9 | 27.0 ± 3.7 |
| Male/female | 55/27 (67.1 %/32.9 %) | 44/25 (63.8 %/36.2 %) | 11/2 (84.6 %15.4 %) |
| Diabetes mellitus/impaired glucose tolerance | 30 (36.6 %) | 25 (36.2 %) | 5 (38.5 %) |
| Hypertension | 71 (86.6 %) | 59 (85.5 %) | 12 (92.3 %) |
| Hyperlipidaemia | 24 (29.3 %) | 19 (27.5 %) | 5 (28.5 %) |
| Hypercholesterolaemia | 14 (17.1 %) | 13 (18.8 %) | 1 (7.7 %) |
| Co-medications | |||
| Statins | |||
| Atorvastatin | 53 (64.6 %) | 44 (63.8 %) | 9 (69.2 %) |
| Simvastatin | 10 (12.2 %) | 10 (14.5 %) | 0 |
| Rosuvastatin | 14 (17.1 %) | 11 (15.9 %) | 3 (23.1 %) |
| PPI | 44 (53.7 %) | 37 (53.6 %) | 7 (53.8 %) |
| CCB | 23 (28.0 %) | 21 (30.4 %) | 2 (15.4 %) |
| ARB | 11 (13.4 %) | 11 (15.9 %) | 0 |
| ACE-I | 61 (74.4 %) | 53 (76.8 %) | 8 (61.5 %) |
| BB | 74 (90.2 %) | 63 (91.3 %) | 11 (84.6 %) |
| Allele frequencies | wt = 0.921 | *1G = 0.179 | |
Age and BMI are presented as mean ± standard deviation
PPI proton pump inhibitor, CCB calcium channel blocker, ARB angiotensin receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, BB beta blocker, wt wild-type allele